|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings indicated that the study of bioactive MIS/AMH, as a possible treatment for tumors expressing the MIS/AMH receptor, is essential.
|
30655798 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The disease-related structural isoform of MIF (oxMIF) can be specifically and predominantly detected in the circulation of patients with inflammatory diseases and in tumor tissue, whereas the ubiquitously expressed isoform of MIF (redMIF) is abundantly expressed in healthy and diseased subjects.
|
29412660 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These transcriptome analyses support previous observations that MIS functions as a tumor suppressor, potentially by regulating signaling pathways that could contribute to endometrial carcinogenesis, and indicating that MIS should be considered as a potential treatment for endometrial cancer.
|
25760378 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data suggest that MIS may be used as a biological modifier or therapeutic modulator on MISRII-expressing tumors in the future.
|
22344630 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MIS also can induce the cell cycle arrest and apoptosis in müllerian duct-derived tumors in vivo and in vitro.
|
22761458 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study investigated the expression patterns of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor (MIS/AMHRII) and mRNA in various types of ovarian neoplasia and evaluated the clinical significance of MIS/AMH as a biological response modifier for MIS/AMHR-positive tumors.
|
19424576 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Wr-T-mediated transport of both p14(ARF) and p16(INK4a) functional peptides (p14-1C and p16-MIS, respectively) into human glioblastoma cell line, U87DeltaEGFR, reversed specific loss of p14 and p16 function, thereby drastically inhibiting tumor growth by >95% within the first 72 h, whereas the growth inhibition was approximately 40% by p14 or p16 single-peptide introduction.
|
18566217 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, elevation of serum MIS above the normal female range was consistently associated with the presence of testicular tissue or MIS- secreting tumors, mandating additional evaluation and surgical exploration.
|
12574214 |
2003 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The molecular analyses of MIS and MIS receptor gene mutations and persistent Mullerian duct syndrome and the development of MIS ELISAs to evaluate testicular function as well as to follow the progress of gonadal tumors are several clear examples of successes over the years.
|
12575754 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Growth of the IGROV-1 tumors was significantly inhibited in the animals with a polymer-cell graft of MIS-producing cells, compared with controls.
|
11248058 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Since the purification protocol of MIS RR is less complicated than that for wild-type MIS, which requires subsequent enzymatic activation, MIS RR can be used for scale-up production with increased yields for further therapeutic trials against MIS-sensitive tumors.
|
9815990 |
1995 |